221 related articles for article (PubMed ID: 23219766)
21. [Health economics research in the area of chronic polyarthritis].
Merkesdal S; Ruof J; Mittendorf T; Mau W; Zeidler H
Z Rheumatol; 2002 Feb; 61(1):21-9. PubMed ID: 11974488
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed MT; Dijkmans BA
Drugs; 2005; 65(5):661-94. PubMed ID: 15748099
[TBL] [Abstract][Full Text] [Related]
23. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
Saraux A; Gossec L; Goupille P; Bregman B; Boccard E; Dupont D; Beresniak A
Rheumatology (Oxford); 2010 Apr; 49(4):733-40. PubMed ID: 20081224
[TBL] [Abstract][Full Text] [Related]
25. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
[TBL] [Abstract][Full Text] [Related]
26. The social cost of rheumatoid arthritis in Italy: the results of an estimation exercise.
Turchetti G; Bellelli S; Mosca M
Reumatismo; 2014 Mar; 65(6):271-7. PubMed ID: 24705030
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
Cárdenas M; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
Rheumatol Int; 2016 Dec; 36(12):1627-1632. PubMed ID: 27778067
[TBL] [Abstract][Full Text] [Related]
28. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
30. Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
Syngle A; Kaur S; Verma I; Syngle T; Syngle V
Clin Rheumatol; 2017 Aug; 36(8):1715-1720. PubMed ID: 28634699
[TBL] [Abstract][Full Text] [Related]
31. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
Tsao NW; Bansback NJ; Shojania K; Marra CA
Best Pract Res Clin Rheumatol; 2012 Oct; 26(5):659-76. PubMed ID: 23218430
[TBL] [Abstract][Full Text] [Related]
32. Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?
Levesque MC
BioDrugs; 2012 Apr; 26(2):65-70. PubMed ID: 22385403
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
34. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
36. Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis.
Osiri M; Kamolratanakul P; Maetzel A; Tugwell P
Rheumatol Int; 2007 Sep; 27(11):1063-9. PubMed ID: 17440729
[TBL] [Abstract][Full Text] [Related]
37. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
[TBL] [Abstract][Full Text] [Related]
38. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
[TBL] [Abstract][Full Text] [Related]
39. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis.
Fries JF
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I86-9. PubMed ID: 10577980
[No Abstract] [Full Text] [Related]
40. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
Mora C; González A; Díaz J; Quintana G
Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
